Inactive Instrument

Big Rock Partners Acquisition Corp. Stock Nasdaq

Equities

BRPAU

US0894822024

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * - Sales 2025 * - Capitalization 33.14M 45.22M
Net income 2024 * -21M -28.65M Net income 2025 * -21M -28.65M EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-1.46 x
P/E ratio 2025 *
-1.51 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
NRx Pharmaceuticals Shares Rise 38% After Positive Drug Trial Data DJ
NRx Pharmaceuticals, Inc. Announces Final Clinical Trial Results CI
NRx Pharmaceuticals, Inc. Announces Promising Findings in Phase 2B/3 Clinical Trial of Nrx-101 Vs. Lurasidone for Treatment of Suicidal Bipolar Depression CI
NRx Pharmaceuticals Receives Notice of Listing Compliance From Nasdaq MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Fed Policymakers Speeches MT
Top Premarket Decliners MT
NRx Pharmaceuticals Looking to Sell Shares to Fund General Corporate Activities; Shares Slump Premarket MT
NRx Pharmaceuticals Looking to Sell Shares to Fund General Corporate Activities, Working Capital MT
NRx Pharmaceuticals, Inc. Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics CI
NRx Pharmaceuticals, Inc. Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine) CI
NRx Pharmaceuticals, Inc. Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression CI
Transcript : NRx Pharmaceuticals, Inc., Q4 2023 Earnings Call, Apr 01, 2024
NRx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : NRx Pharmaceuticals, Inc. - Shareholder/Analyst Call
NRx Pharmaceuticals, Inc., Conversio Health, LLC and Nephron Pharmaceuticals Corporation Complete Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine) CI
More news

Latest transcript on Big Rock Partners Acquisition Corp.

Big Rock Partners Acquisition Corp. is a blank check company. The Company is formed for the purpose of entering into a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities. The Company is not limited to a particular industry or geographic region for purposes of consummating a business combination. The Company has not commenced any business operation and has not generated any revenue.
Sector
-
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW